2013 Fiscal Year Final Research Report

Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors

Research Project

Project/Area Number	23591763
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Radiation science
Research Institution	Shiga University of Medical Science
Principal Investigator	SHINICHI Ota 滋賀医科大学, 医学部, 講師 (30583637)
Co-Investigator(Kenkyū-buntansha)	SONODA Akinaga 滋賀医科大学, 医学部, 助教 (00571051)
Co-Investigator(Renkei-kenkyūsha)	NITTA Norihisa 滋賀医科大学, 医学部, 講師 (40324587)
Project Period (FY)	2011 – 2013
Keywords	血管新生阻害薬 / 抗腫瘍効果
Research Abstract	The anti-tumor effect of the angiogenesis inhibitors increased in the following order; bevacizumab, sorafenib, and thalidomide. The anti-tumor effects of the dual therapies except sorafenib and thalidomide were lower than those of the single therapies. However, the numbers of the dual therapies were not enough to consider them, therefore, more studies about the dual therapies were necessary. When the anti-tumor effect of the angiogenesis inhibitor was determined, the best and simple way was to measure the change of the tumor sizes before and after the therapy using CT. To measure the change of enhancement ratio using CT / DSA and to evaluate the necrosis ratio and the numbers of tumor vessels pathologically were unfitted for the response evaluation of the angiogenesis inhibitors.